Madrigal Pharmaceuticals (NASDAQ:MDGL) will report Q2 results July 30 and host an 8:00 a.m. ET webcast as it advances Rezdiffra (resmetirom) commercially and in a Phase 3 outcomes trial, secures three resmetirom patents through 2042–2045, and partners with Pfizer on ervogastat combination data due later this year.
Previous Week Recap
- Madrigal Q2 2026 Results, July 30: Madrigal Pharmaceuticals (MDGL) will report Q2 2026 results July 30 before market open with an 8:00 a.m. ET webcast. Commercial focus: Rezdiffra (resmetirom) for MASH; Phase 3 outcomes trial ongoing.
- Resmetirom Patents Granted USPTO: Madrigal (MDGL): USPTO issued three resmetirom patents—two covering dosing with CYP2C8 inhibitor and rosuvastatin (protection to 2045/2042) and one for treating F4c cirrhosis (protection to 2042).
- Ervogastat Licensed To Pfizer: Madrigal Pharmaceuticals (MDGL) licensed ervogastat to Pfizer to study it with Pfizer’s Rezdiffra in moderate to advanced liver fibrosis; interaction data from those trials expected later this year
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.